Open AccessAnorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?
Author(s) -
Mohammad Adileh,
Jonathan B. Yuval,
Shan Huang,
Alexander N. Shoushtari,
Felipe Quezada-Díaz,
Emmanouil P. Pappou,
Martin R. Weiser,
Julio GarciaAguilar,
Julius Smith,
Philip B. Paty,
Garrett M. Nash
Publication year - 2021
Publication title -
diseases of the colon and rectum
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.575
H-Index - 162
eISSN - 1530-0358
pISSN - 0012-3706
DOI - 10.1097/dcr.0000000000001872
Subject(s) - medicine , immune checkpoint , oncology , melanoma , immune system , regimen , surgical oncology , neoadjuvant therapy , immunotherapy , cancer , immunology , cancer research , breast cancer
The advent of immune checkpoint inhibition therapy has dramatically improved survival in patients with skin melanoma. Survival outcomes after resection of anorectal melanoma treated with immune checkpoint inhibition have not been reported.